Envisagenics
Biotechnology, 335 Madison Ave Fl 16, New York, 10017, United States, 11-50 Employees
Phone Number: 51********
Who is ENVISAGENICS
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative ther...
Read More
-
Headquarters: 335 Madison Ave Fl 16, New York, New York, 10017, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ENVISAGENICS
Envisagenics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Envisagenics
Answer: Envisagenics's headquarters are located at 335 Madison Ave Fl 16, New York, 10017, United States
Answer: Envisagenics's phone number is 51********
Answer: Envisagenics's official website is https://envisagenics.com
Answer: Envisagenics's revenue is $5 Million to $10 Million
Answer: Envisagenics's SIC: 8731
Answer: Envisagenics has 11-50 employees
Answer: Envisagenics is in Biotechnology
Answer: Envisagenics contact info: Phone number: 51******** Website: https://envisagenics.com
Answer: Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month